Farnesyltransferase catalyses the post-translational modification of p
roteins by a cholesterol precursor, farnesylpyrophosphate. One of the
substrates of this enzyme is the product of the ras oncogene. Recently
, inhibitors of farnesyltransferase have been identified through two d
ifferent approaches: microbial screens for natural compounds, and subs
trate analogues. These inhibitors may be useful in blocking the action
of Ras proteins, in further characterizing protein prenyltransferases
, and in elucidating the regulation of cholesterol metabolism.